Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Doree to lead US sales of stomach cancer breath test

This article was originally published in Clinica

Executive Summary

Exalenz Bioscience is forging ahead with the US commercialization of its BreathID Hp breath test for managing gastrointestinal conditions, having appointed a new vice-president of sales, Gavin Doree, to lead the charge. Mr Doree will head the company’s newly established direct sales organization in the US, based in New Jersey. His appointment coincides with the worldwide launch of the second-generation BreathID Hp device, which uses the real-time, continuous breath of the patient to detect the presence of the H pylori bacteria associated with various illnesses including peptic ulcers and stomach cancer. Prior to joining Israel-headquartered Exalenz, Mr Doree was national director and director of strategic accounts at Medivators, a Minneapolis, Minnesota specialist in infection prevention technologies.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT100653

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel